Key points from article :
Researchers at Scripps Research developed a drug-like molecule that stimulates the growth of lung stem cells. This has the potential to repair damaged lung tissue, which could be beneficial in treating diseases like idiopathic pulmonary fibrosis (IPF).
The current treatment focus for lung diseases is slowing progression rather than regeneration. This new approach could change the way severe lung diseases are treated.
The team discovered that a class of drugs used for diabetes, DPP4 inhibitors, could promote activation of lung stem cells. However, the required doses would be too high for safe human use.
A new prototype drug, NZ-97, was developed to target the lungs specifically and promote stem cell growth. It is similar to CMR316, a drug entering clinical trials soon.
CMR316 will be administered directly to the lungs weekly via a nebulizer. This targeted delivery allows for very low, safe doses of the drug.
The researchers hope CMR316 can help treat a range of lung diseases, including IPF, influenza, COVID-19, and chronic obstructive pulmonary disease (COPD).
This research was published in the Proceedings of the National Academy of Sciences.
